IP Library › Granted Patent US 12,564,664
Granted Patent B2
US 12,564,664 · App. 18/200,666 · Granted Mar 3, 2026

Treatment fluid devices methods and systems

Inventors: Orlando Soto (Amesbury, MA); Joseph Rausa (Nashua, NH); James M. Brugger (Newburyport, MA); William J. Schnell (Libertyville, IL); Goetz Friederichs (Beverly, MA); Jeffrey H. Burbank (Manchester, MA); Joseph E. Turk, Jr. (North Andover, MA); Scott W. Newell (Ipswich, MA); Amanda Wozniak (Somerville, MA)
Assignee: NxStage Medical, Inc.
A61M1/1668A61M1/154A61M1/155A61M1/1561A61M1/1562A61M1/1565A61M1/1601A61M1/1605A61M1/1666A61M5/14228A61M2205/12A61M2205/3317A61M2205/3368
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,664
App. No.
18/200,666
Granted
Mar 3, 2026
Kind
B2
Abstract

A conductivity measurement device includes first and second conductivity measurement flow channels positioned in a fluid circuit and fluidly linked for fluid flow between the first and second conductivity measurement flow channels. A controller having a current source connected to the first and second conductivity channels applies alternating voltages at frequencies that are different, each being respective to one of the first and second conductivity cells.

Claims (24)

1 . A method of providing dialysate, comprising:

filling first and second containers with first and second concentrate components for a sodium lactate-based dialysate solution, the first and second concentrate components, when combined in a predefined ratio and diluted with water, forming a functional dialysate suitable for a dialysis treatment;

the first and second concentrate components being constituted such that sodium lactate is at least partly separated from sodium chloride and glucose to an extent such that no precipitation occurs in either container after storage for a period of at least two days while a level of concentration of the first and second concentrate components are such that if the first and second concentrate components are combined and stored for the period of at least two days, a precipitation would occur in a combination of the first and second concentrate components.

2 . The method of claim 1 , further comprising providing the first and second containers to a treatment site and combining and diluting the first and second concentrate components to form a dialysate for treatment.

3 . The method of claim 1 , further comprising, sterilizing internal surfaces of said first and second containers prior to said filling.

4 . The method of claim 3 , further comprising, sterile filtering said first and second concentrate components prior to said filling.

5 . The method of claim 1 , wherein the first concentrate component includes sodium chloride and glucose and the second concentrate component includes sodium lactate.

6 . The method of claim 5 , wherein the sodium lactate has a concentration of at least 35 mEq.

7 . The method of claim 6 , wherein the second concentrate component includes no glucose.

8 . The method of claim 7 , wherein the second concentrate component includes no sodium chloride.

9 . The method of claim 1 , wherein the first and second concentrate components contain glucose and the second concentrate contains no sodium chloride.

10 . The method of claim 9 , wherein the second concentrate component contains less glucose than the first concentrate component.

11 . The method of claim 1 , wherein the first and second concentrate components both contain sodium lactate, the second concentrate component containing a higher concentration of sodium lactate than the first concentrate component.

12 . A dialysate concentrate article of manufacture, comprising:

first and second containers containing first and second concentrate components for a sodium lactate-based dialysate solution, the first and second concentrate components, when combined in a predefined ratio and diluted with water, forming a functional dialysate suitable for a dialysis treatment;

the first and second concentrate components being constituted such that sodium lactate is at least partly separated from sodium chloride and glucose to an extent such that no precipitation occurs in either container after storage for a period of at least two days while a level of concentration of the first and second concentrate components are such that if the first and second concentrate components are combined and stored for the period of at least two days, a precipitation would occur in a combination of the first and second concentrate components.

13 . The article of manufacture of claim 12 , wherein the first and second containers are suitable for storage and transport to a treatment site and are constructed for connection to a predefined system for diluting the first and second concentrate components to form a dialysate for treatment.

14 . The article of manufacture of claim 12 , wherein internal surfaces of said first and second containers are sterile.

15 . The article of manufacture of claim 12 , wherein the first concentrate component includes sodium chloride and glucose and the second concentrate component includes sodium lactate.

16 . The article of manufacture of claim 12 , wherein the first concentrate component includes sodium chloride and glucose and the second concentrate component includes sodium lactate at a concentration of at least 35 mEq.

17 . The article of manufacture of claim 16 , wherein the second concentrate component includes no sodium chloride.

18 . The article of manufacture of claim 16 , wherein the second concentrate component includes no glucose.

19 . The article of manufacture of claim 12 , wherein the second concentrate component contains less glucose than the first concentrate component.

20 . The article of manufacture of claim 12 , wherein the first and second concentrate components both contain sodium lactate, the second concentrate component containing a higher concentration of sodium lactate than the first concentrate component.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: SOTO, ORLANDO; RAUSA, JOSEPH; BRUGGER, JAMES M.; SCHNELL, WILLIAM J.; FRIEDERICHS, GOETZ; BURBANK, JEFFREY H.; TURK, JOSEPH E., JR.; NEWELL, SCOTT W.; WOZNIAK, AMANDA
To: NXSTAGE MEDICAL, INC.
Reel/Frame 063726/0083 →
Continuity (7)
Continuation 16712385 · Dec 12, 2019
Division 15337999 · Oct 28, 2016
Provisional Application 62297514 · Feb 19, 2016
Provisional Application 62253650 · Nov 10, 2015
Provisional Application 62249324 · Nov 1, 2015
Provisional Application 62248764 · Oct 30, 2015
Related Publication 20230293794A1 · Sep 21, 2023
References Cited (49)
US 2600324A · Rappaport · 1952 [cited by applicant]
US 3352779A · Austin et al. · 1967 [cited by applicant]
US 3701006A · Volkel et al. · 1972 [cited by applicant]
US 3774762A · Lichtenstein · 1973 [cited by applicant]
US 3912455A · Lichtenstein · 1975 [cited by applicant]
US 4351731A · Perrot · 1982 [cited by applicant]
US 4370983A · Lichtenstein · 1983 [cited by applicant]
US 4817629A · Davis et al. · 1989 [cited by applicant]
US 5158437A · Natwick et al. · 1992 [cited by applicant]
US 5223114A · Zare et al. · 1993 [cited by applicant]
US 5244568A · Lindsay et al. · 1993 [cited by applicant]
US 5247434A · Peterson et al. · 1993 [cited by applicant]
US 5762782A · Kenley et al. · 1998 [cited by applicant]
US 6122599A · Mehta · 2000 [cited by applicant]
US 6607697B1 · Müller · 2003 [cited by applicant]
US 6635026B1 · Béné · 2003 [cited by applicant]
US 6793827B1 · Bosetto et al. · 2004 [cited by applicant]
US 6939471B2 · Gross et al. · 2005 [cited by applicant]
US 6979309B2 · Burbank et al. · 2005 [cited by applicant]
US 7780619B2 · Brugger et al. · 2010 [cited by applicant]
US 8525533B2 · Sullivan · 2013 [cited by applicant]
US 10478544B2 · Friederichs et al. · 2019 [cited by applicant]
US 11167069B2 · Friederichs et al. · 2021 [cited by applicant]
US 11400194B2 · Brugger et al. · 2022 [cited by applicant]
US 20020088752A1 · Balschat et al. · 2002 [cited by applicant]
US 20020127144A1 · Mehta · 2002 [cited by applicant]
US 20020158635A1 · Higo · 2002 [cited by applicant]
US 20040231425A1 · Mizuno et al. · 2004 [cited by applicant]
US 20050020507A1 · Zieske · 2005 [cited by examiner]
US 20070163712A1 · Gotkis et al. · 2007 [cited by applicant]
US 20070293441A1 · Choo · 2007 [cited by examiner]
US 20080015493A1 · Childers et al. · 2008 [cited by applicant]
US 20080208111A1 · Kamen et al. · 2008 [cited by applicant]
US 20090010627A1 · Lindsay et al. · 2009 [cited by applicant]
US 20090320684A1 · Weaver et al. · 2009 [cited by applicant]
US 20100217148A1 · Binder · 2010 [cited by applicant]
US 20110186517A1 · Hedmann et al. · 2011 [cited by applicant]
US 20110284464A1 · Roncadi et al. · 2011 [cited by applicant]
US 20110315611A1 · Fulkerson et al. · 2011 [cited by applicant]
US 20120279910A1 · Wallace et al. · 2012 [cited by applicant]
US 20130134077A1 · Wieskotten et al. · 2013 [cited by applicant]
US 20140018727A1 · Burbank et al. · 2014 [cited by applicant]
US 20140210494A1 · Ghods et al. · 2014 [cited by applicant]
US 20140263017A1 · Jones et al. · 2014 [cited by applicant]
US 20140263063A1 · Jones et al. · 2014 [cited by applicant]
US 20140263064A1 · Jones et al. · 2014 [cited by applicant]
US 20150129499A1 · Bene · 2015 [cited by applicant]
US 20170290970A1 · Friederichs et al. · 2017 [cited by applicant]
US 20210308349A1 · Wyeth et al. · 2021 [cited by applicant]